Edwin Choy, MD
Hematology & Oncology · Boston, MANPI 1760466106
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Daiichi Sankyo Inc. at 26.6% of the total. Reporting peaked in 2024 at $9,895 and has fallen 93.9% since, to $606 in 2025.
Across 23 payments — averaging $752.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$5K
- Ipsen Biopharmaceuticals, Inc$4K
- Springworks Therapeutics, Inc.$3K
- Deciphera Pharmaceuticals Inc.$3K
- Bayer$2K
- Icotec Medical Inc.$437
- plus $301 from 3 others
Across 36 payments — averaging $11,857 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$298K
- Karyopharm Therapeutics Inc.$57K
- Boehringer Ingelheim$38K
- AstraZeneca$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Amgen$3K
- plus $1K from 1 others
What the payments were for
- Consulting fees$7,07341%
- Speaking & faculty fees$8,25948%
- Travel & lodging$8425%
- Food & beverage$1,0406%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $4,613 |
| Ipsen Biopharmaceuticals, Inc | 4 | $3,738 |
| Springworks Therapeutics, Inc. | 1 | $3,360 |
| Deciphera Pharmaceuticals Inc. | 5 | $2,764 |
| Bayer | 1 | $2,100 |
| Icotec Medical Inc. | 7 | $437 |
| Tempus AI, Inc | 1 | $114 |
| Epizyme, Inc. | 1 | $99 |
| Aadi Bioscience, Inc. | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAZVERIK$3,626
- OGSIVEO$3,360
- VIMSELTINIB$2,597
- Vitrakvi$2,100
- Turalio$1,613
- VADER PEDICLE SYSTEM 6.0, SCREW, Carbon/PEEK, POLYAX., FEN., O 5.5 X 45 MM$137
- VADER PEDICLE SYSTEM, ROD, Carbon/PEEK, CURVED, 6.0 R450 X 200 MM$137
- KONG-TL VBR E, EXPANDABLE BODY, L, 19 MM X 27 - 37 MM$137
- KONG-TL VBR, END PLATE, ROUND, L AND SCREW, 12 X 43 MM$137
- KONG-TL VBR, END PLATE, RECTANGULAR, M AND SCREW, 12 X 33 MM$137
- XT CDX$114
How this compares
$17,313 in reported general payments places this provider in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sunitinib Malate | 13 | $69,376 |
| SorafenibSorafenib Tosylate | 17 | $66,683 |
| Imatinib Mesylate | 89 | $66,161 |
| TuralioPexidartinib Hydrochloride | 11 | $61,620 |
| EliquisApixaban | 32 | $18,789 |
| XareltoRivaroxaban | 12 | $9,609 |
| Prochlorperazine Maleate | 17 | $314 |
| Dexamethasone | 14 | $135 |
| Ondansetron Hcl | 14 | $117 |
| Lorazepam | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Daiichi Sankyo Inc.Turalio | $4,613 | $61,62011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.